Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Dec 5, 2019Latest Initiative of #ThisIsMBC to be Unveiled at the 2019 San Antonio Breast Cancer Symposium
Eisai Inc. and METAvivor today announced the launch of Beneath the Breast, a new initiative of the #ThisIsMBC campaign. Beneath the Breast spotlights imagery of eight people living with metastatic...
-
Sep 29, 2019
KENILWORTH, N.J., and WOODCLIFF LAKE, N.J., Sept. 29, 2019 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced final results from the full...
Sep 24, 2019- Data includes an oral presentation from full advanced endometrial carcinoma (EC) cohort of Phase 1b/2 study of KEYTRUDA plus LENVIMAEisai today announced the presentation of new data and analyses via one oral proffered paper presentation, four poster discussions and seven poster presentations at the 2019 European Society for...
-
Sep 17, 2019Combination Treatment Approved for Patients with Advanced Endometrial Carcinoma That Is Not Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR), Who Have Disease Progression Following Prior Systemic Therapy and Are Not Candidates for Curative Surgery or Radiation
KENILWORTH, N.J., and WOODCLIFF LAKE, N.J., Sept. 17, 2019 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced that the U.S. Food and Drug...
-
Jul 23, 2019Designation Granted for Potential First-Line Treatment of Patients with Advanced Unresectable Hepatocellular Carcinoma Not Amenable to Locoregional Treatment
Kenilworth, N.J., and Woodcliff Lake, N.J., July 23, 2019 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced that the U.S. Food and Drug...